Booster vaccination and post COVID-19 condition during the Omicron variant-dominant wave: A large population-based study

Clin Microbiol Infect. 2024 Dec 9:S1198-743X(24)00588-3. doi: 10.1016/j.cmi.2024.12.002. Online ahead of print.

Abstract

Objectives: The effect of the COVID-19 booster vaccination and the long-term consequences concerning preventing post COVID-19 condition (PCC) remain unclear. We aimed to investigate the association of COVID-19 booster vaccination dose and vaccination timing before infection with the risk of PCC during the Omicron variant-dominant wave.

Methods: This population-based study included confirmed COVID-19 patients (extracted from the Health Center Real-time Information-sharing System) aged 20-69 years, who were infected between July 1 and August 31, 2022. We used a self-report questionnaire to evaluate PCC and extracted information on vaccination from the municipal vaccine registry system. We calculated multiple propensity scores for COVID-19 vaccination status (unvaccinated, 1-2 doses, ≥3 doses) to control for baseline population differences. We then used a logistic regression model with inverse probability weighting to analyse the associations between the number of vaccine doses and the risk of PCC. Additionally, we conducted stratified analysis by gender and subgroup analysis for respiratory and neurological symptoms. Multivariable logistic regression was used to analyse the association between vaccination timing and PCC risk, adjusting for vaccination doses.

Results: Of the 7,936 participants with COVID-19 (mean age 42.9 years, 4,553 women), 940 (11.8%) had at least one PCC. Compared with people unvaccinated, those vaccinated ≥3 times before the infection had a lower probability of PCC with the odds ratio (OR) of 0.70 (95% confidence interval (CI) 0.53-0.90), although we detected no association with one or two doses. This association was present in women (≥3 doses vs. unvaccinated OR 0.70, 95% CI 0.51-0.95) but not in men. Those vaccinated ≥3 times had fewer neurological symptoms compared to those unvaccinated (OR 0.61, 95% CI 0.45-0.83); however, no significant association was found for respiratory symptoms.

Conclusions: This study suggests that booster vaccination could lower the risk of PCC.

Keywords: Japan; booster vaccine; population study; post COVID-19 condition; vaccination effect.